About AbbVie (ABBV)

AbbVie Inc. (ABBV) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of advanced therapies for a wide range of medical conditions. The company was established in 2013 as a spin-off from Abbott Laboratories, and it has since emerged as a leader in the pharmaceutical industry. AbbVie is best known for its flagship product, Humira, which is the world's top-selling prescription medicine. Humira is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. In addition to Humira, AbbVie has a diverse portfolio of innovative drugs that address other therapeutic areas, such as oncology, immunology, and neuroscience.

AbbVie's success is driven by its strong research and development capabilities, as well as its focus on strategic acquisitions and partnerships. The company invests heavily in scientific research and has a robust pipeline of potential new drugs. AbbVie also seeks to expand its portfolio through targeted acquisitions of complementary companies. For example, in 2019, AbbVie completed its acquisition of Allergan plc, a leading global pharmaceutical company, to enhance its position in the aesthetics and eye care markets. This acquisition added several popular brands to AbbVie's portfolio, such as Botox and Juvederm.